Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by gram-positive pathogens

Yao Shen Chen, Sai Cheong Lee, Woo Joo Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background and Purpose: Linezolid, an oxazolidonone, has shown efficacy in the treatment of adults with nosocomial or community-acquired pnemonia; skin and soft tissue infections and infections due to methicillin-resistant Staphylococcus aureus. The purpose of this open-label, single-arm, multicenter study was to evaluate the efficacy and tolerability of linezolid in patients from the Asia-Pacific Region with severe Gram-positive skin and soft tissue infections. Methods: 166 patients at 27 sites in 7 countries from the Asia-Pacific region were enrolled. The patients has severe skin infection involving the deeper layers or extensive surface area. Patients received 7 to 28 days of treatment with linezolid by clinical judgment. All patient received intravenous linezolid 600 mg twice a day initially and were switched over to an equivalent oral dose (60 mg twice a day) when the investigator discerned clinical improvement. The primary efficacy endpoint in this study was clinical outcome at the follow-up visit, 14 to 21 days after completion of treatment (test of cure), and the secondary efficacy variable was microbiologic response at test-of cure. Results: 166 patients received the study medication and were included in the intent-to-treat analysis. The clinical success rate was approximately 93% in both the intern-to-treat and clinically evaluable populations at the end of treatment and test-of-cure visits. In the modified intent-to-treat and microbiologically evaluable populations, the microbiologic success rates at the test-of cure visit were 88.9% and 93.8%, respectively. The most frequent treatment-emergent adverse events were nausea (13%), dizziness (8%), anemia (7%), and vomiting (5%). Conclusions: Linezolid was effective and well tolerated in patients with severe skin and soft tissue infections caused by Gram-positive pathogens.

Original languageEnglish
Pages (from-to)349-354
Number of pages6
JournalJournal of the Formosan Medical Association
Volume103
Issue number5
Publication statusPublished - 2004 May 1

Fingerprint

Linezolid
Soft Tissue Infections
Skin
Dizziness
Therapeutics
Methicillin-Resistant Staphylococcus aureus
Infection
Nausea
Population
Multicenter Studies
Vomiting
Anemia

Keywords

  • Bacterial
  • Linezolid
  • Oxazolidinones
  • Skin diseases
  • Soft tissue infections
  • Treatment outcome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by gram-positive pathogens. / Chen, Yao Shen; Lee, Sai Cheong; Kim, Woo Joo.

In: Journal of the Formosan Medical Association, Vol. 103, No. 5, 01.05.2004, p. 349-354.

Research output: Contribution to journalArticle

@article{15d0cbe9f4634811a00aa50bba1fcc94,
title = "Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by gram-positive pathogens",
abstract = "Background and Purpose: Linezolid, an oxazolidonone, has shown efficacy in the treatment of adults with nosocomial or community-acquired pnemonia; skin and soft tissue infections and infections due to methicillin-resistant Staphylococcus aureus. The purpose of this open-label, single-arm, multicenter study was to evaluate the efficacy and tolerability of linezolid in patients from the Asia-Pacific Region with severe Gram-positive skin and soft tissue infections. Methods: 166 patients at 27 sites in 7 countries from the Asia-Pacific region were enrolled. The patients has severe skin infection involving the deeper layers or extensive surface area. Patients received 7 to 28 days of treatment with linezolid by clinical judgment. All patient received intravenous linezolid 600 mg twice a day initially and were switched over to an equivalent oral dose (60 mg twice a day) when the investigator discerned clinical improvement. The primary efficacy endpoint in this study was clinical outcome at the follow-up visit, 14 to 21 days after completion of treatment (test of cure), and the secondary efficacy variable was microbiologic response at test-of cure. Results: 166 patients received the study medication and were included in the intent-to-treat analysis. The clinical success rate was approximately 93{\%} in both the intern-to-treat and clinically evaluable populations at the end of treatment and test-of-cure visits. In the modified intent-to-treat and microbiologically evaluable populations, the microbiologic success rates at the test-of cure visit were 88.9{\%} and 93.8{\%}, respectively. The most frequent treatment-emergent adverse events were nausea (13{\%}), dizziness (8{\%}), anemia (7{\%}), and vomiting (5{\%}). Conclusions: Linezolid was effective and well tolerated in patients with severe skin and soft tissue infections caused by Gram-positive pathogens.",
keywords = "Bacterial, Linezolid, Oxazolidinones, Skin diseases, Soft tissue infections, Treatment outcome",
author = "Chen, {Yao Shen} and Lee, {Sai Cheong} and Kim, {Woo Joo}",
year = "2004",
month = "5",
day = "1",
language = "English",
volume = "103",
pages = "349--354",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Excerpta Medica Asia Ltd.",
number = "5",

}

TY - JOUR

T1 - Efficacy and tolerability of linezolid in treating severe skin and soft tissue infections caused by gram-positive pathogens

AU - Chen, Yao Shen

AU - Lee, Sai Cheong

AU - Kim, Woo Joo

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Background and Purpose: Linezolid, an oxazolidonone, has shown efficacy in the treatment of adults with nosocomial or community-acquired pnemonia; skin and soft tissue infections and infections due to methicillin-resistant Staphylococcus aureus. The purpose of this open-label, single-arm, multicenter study was to evaluate the efficacy and tolerability of linezolid in patients from the Asia-Pacific Region with severe Gram-positive skin and soft tissue infections. Methods: 166 patients at 27 sites in 7 countries from the Asia-Pacific region were enrolled. The patients has severe skin infection involving the deeper layers or extensive surface area. Patients received 7 to 28 days of treatment with linezolid by clinical judgment. All patient received intravenous linezolid 600 mg twice a day initially and were switched over to an equivalent oral dose (60 mg twice a day) when the investigator discerned clinical improvement. The primary efficacy endpoint in this study was clinical outcome at the follow-up visit, 14 to 21 days after completion of treatment (test of cure), and the secondary efficacy variable was microbiologic response at test-of cure. Results: 166 patients received the study medication and were included in the intent-to-treat analysis. The clinical success rate was approximately 93% in both the intern-to-treat and clinically evaluable populations at the end of treatment and test-of-cure visits. In the modified intent-to-treat and microbiologically evaluable populations, the microbiologic success rates at the test-of cure visit were 88.9% and 93.8%, respectively. The most frequent treatment-emergent adverse events were nausea (13%), dizziness (8%), anemia (7%), and vomiting (5%). Conclusions: Linezolid was effective and well tolerated in patients with severe skin and soft tissue infections caused by Gram-positive pathogens.

AB - Background and Purpose: Linezolid, an oxazolidonone, has shown efficacy in the treatment of adults with nosocomial or community-acquired pnemonia; skin and soft tissue infections and infections due to methicillin-resistant Staphylococcus aureus. The purpose of this open-label, single-arm, multicenter study was to evaluate the efficacy and tolerability of linezolid in patients from the Asia-Pacific Region with severe Gram-positive skin and soft tissue infections. Methods: 166 patients at 27 sites in 7 countries from the Asia-Pacific region were enrolled. The patients has severe skin infection involving the deeper layers or extensive surface area. Patients received 7 to 28 days of treatment with linezolid by clinical judgment. All patient received intravenous linezolid 600 mg twice a day initially and were switched over to an equivalent oral dose (60 mg twice a day) when the investigator discerned clinical improvement. The primary efficacy endpoint in this study was clinical outcome at the follow-up visit, 14 to 21 days after completion of treatment (test of cure), and the secondary efficacy variable was microbiologic response at test-of cure. Results: 166 patients received the study medication and were included in the intent-to-treat analysis. The clinical success rate was approximately 93% in both the intern-to-treat and clinically evaluable populations at the end of treatment and test-of-cure visits. In the modified intent-to-treat and microbiologically evaluable populations, the microbiologic success rates at the test-of cure visit were 88.9% and 93.8%, respectively. The most frequent treatment-emergent adverse events were nausea (13%), dizziness (8%), anemia (7%), and vomiting (5%). Conclusions: Linezolid was effective and well tolerated in patients with severe skin and soft tissue infections caused by Gram-positive pathogens.

KW - Bacterial

KW - Linezolid

KW - Oxazolidinones

KW - Skin diseases

KW - Soft tissue infections

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=3543083367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543083367&partnerID=8YFLogxK

M3 - Article

VL - 103

SP - 349

EP - 354

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 5

ER -